CLAIMS

1. A pharmaceutical composition comprising:

a) a compound A, which is (2*R*)-2-(4-fluorophenyl)-*N*-[4-(2-{[2-methoxy-4-(methylsulfonyl)phenyl]amino}[1,2,4]triazolo[1,5-*a*]pyridin-6-yl)phenyl]propanamide,

or a salt, hydrate or solvate thereof;

and

b1) a matrix B1, said matrix B1 consisting of

i. 70% to 100% by weight of polyethylene glycol having an average molecular weight of from 100 to 800;
ii. 0% to 30% by weight of polyvinylpyrrolidone; and
iii. 0% to 10% by weight of water; and
iv. 0% to 5% by weight of one or more pharmaceutically acceptable excipients;

wherein the weight ratio of the compound A calculated as a solvent-free base to the matrix B1 is smaller than 20 : 80;

or

b2) a matrix B2, said matrix B2 consisting of

i. 40% to 60% by weight of polyvinylpyrrolidone
ii. 40% to 60% by weight of croscarmellose sodium; and
iii. 0% to 5% by weight of one or more pharmaceutically acceptable excipients;

wherein the weight ratio of the compound A calculated as a solvent-free base to the matrix B2 is smaller than 20 : 80;

or

b3) a matrix B3, said matrix B3 consisting of

i. 95% to 100% by weight of a polyethylene glycol having an average molecular weight of from 4000 to 8000; and

ii. 0% to 5% by weight of one or more pharmaceutically acceptable excipients;

wherein the weight ratio of the compound A calculated as a solvent-free base to the matrix B3 is smaller than 30 : 70.

2. A pharmaceutical composition according to claim 1, comprising a matrix B1; wherein the matrix B1 consists of

i. 80% to 95% by weight of polyethylene glycol;

ii. 0% to 20% by weight of polyvinylpyrrolidone; and

i. 0% to 10% by weight of water; and

ii. 0% to 3% by weight of one or more pharmaceutically acceptable excipients;

wherein the polyethylene glycol has an average molecular weight of from 300 to 500; and wherein the weight ratio of the compound A calculated as a solvent-free base to the matrix B1 is between 1 : 99 to 9 : 91.

3. A pharmaceutical composition according to claim 1, comprising a matrix B2; wherein the matrix B2 consists of

i. 45% to 49% by weight of polyvinylpyrrolidone;

ii. 51% to 55% by weight of croscarmellose sodium; and

iii. 0% to 3% by weight of one or more pharmaceutically acceptable excipients;

wherein the weight ratio of the compound A calculated as a solvent-free base to the matrix B2 is between 1 : 99 to 9 : 91.

4. A pharmaceutical composition according to claim 1, comprising a matrix B3; wherein the matrix B3 consists of 97% to 100% by weight of polyethylene glycol; wherein the polyethylene glycol has an average molecular weight of from 5500 to 6500; and wherein the weight ratio of the compound A calculated as a solvent-free base to the matrix B is between 5 : 95 to 20 : 80.

5. A pharmaceutical composition according to claim 1, consisting of 2% to 3% by weight of a compound A, or a salt, hydrate or solvate thereof, 76% to 79% by weight of polyethylene glycol having an average molecular weight of from 300 to 500, and 18% to 22% by weight of polyvinylpyrrolidone, whith the proviso that the sum of the weight percentages of the ingredients is 100.

6. A pharmaceutical composition according to any one of claims 1 to 5 for use in the treatment or prophylaxis of a disease.

7. The use of a pharmaceutical composition of any one of claims 1 to 5 in the manufacture of a medicament for the prophylaxis or treatment of a haemotological tumour, a solid tumour and/or metastases thereof, *e.g.* leukaemias and myelodysplastic syndrome, malignant lymphomas, head and neck tumours including brain tumours and brain metastases, tumours of the thorax including non-small cell and small cell lung tumours, gastrointestinal tumours, endocrine tumours, mammary and other gynaecological tumours, urological tumours including renal, bladder and prostate tumours, skin tumours, and sarcomas, and/or metastases thereof.